We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
- Authors
Jayasekera, Jinani; Schechter, Clyde B; Sparano, Joseph A; Jagsi, Reshma; White, Julia; Chapman, Judith-Anne W; Whelan, Timothy; Anderson, Stewart J; Fyles, Anthony W; Sauerbrei, Willi; Zellars, Richard C; Li, Yisheng; Song, Juhee; Huang, Xuelin; Julian, Thomas B; Luta, George; Berry, Donald A; Feuer, Eric J; Mandelblatt, Jeanne; Group, CISNET-BOLD Collaborative
- Abstract
<bold>Background: </bold>Radiotherapy after breast conservation has become the standard of care. Prior meta-analyses on effects of radiotherapy predated availability of gene expression profiling (GEP) to assess recurrence risk and/or did not include all relevant outcomes. This analysis used GEP information with pooled individual-level data to evaluate the impact of omitting radiotherapy on recurrence and mortality.<bold>Methods: </bold>We considered trials that evaluated or administered radiotherapy after lumpectomy in women with low-risk breast cancer. Women included had undergone lumpectomy and were treated with hormonal therapy for stage I, ER+ and/or PR+, HER2- breast cancer with Oncotype scores no greater than 18. Recurrence-free interval (RFI), type of RFI (locoregional or distant), and breast cancer-specific and overall survival were compared between no radiotherapy and radiotherapy using adjusted Cox models. All statistical tests were two-sided.<bold>Results: </bold>The final sample included 1778 women from seven trials. Omission of radiotherapy was associated with an overall adjusted hazard ratio of 2.59 (95% confidence interval [CI] = 1.38 to 4.89, P = .003) for RFI. There was a statistically significant increase in any first locoregional recurrence (P = .001), but not distant recurrence events (P = .90), or breast cancer-specific (P = .85) or overall survival (P = .61). Five-year RFI rate was high (93.5% for no radiotherapy vs 97.9% for radiotherapy; absolute reduction = 4.4%, 95% CI = 0.7% to 8.1%, P = .03). The effects of radiotherapy varied across subgroups, with lower RFI rates for those with Oncotype scores of less than 11 (vs 11-18), older (vs younger), and ER+/PR+ status (vs other).<bold>Conclusions: </bold>Omission of radiotherapy in hormone-sensitive patients with low recurrence risk may lead to a modest increase in locoregional recurrence event rates, but does not appear to increase the rate of distant recurrence or death.
- Subjects
RADIOTHERAPY; BREAST cancer treatment; HORMONES; GENE expression; MEDICAL care
- Publication
JNCI: Journal of the National Cancer Institute, 2018, Vol 110, Issue 12, p1370
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djy128